A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513174-22-00

Acronym

ONL1204-GA-002

Enrollment

182

Registered

2025-08-05

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Age-related Macular Degeneration (AMD)

Brief summary

GA lesion area assessment

Interventions

DRUGSham injection

DRUGONL1204 Ophthalmic Solution

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
GA lesion area assessment	—

Countries

Austria, Czechia, Germany, Greece, Hungary, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026